Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Hepatocellular | 19 | 2024 | 2326 | 2.890 |
Why?
|
alpha-Fetoproteins | 15 | 2024 | 229 | 2.830 |
Why?
|
Liver Neoplasms | 18 | 2024 | 4353 | 2.370 |
Why?
|
Breast Neoplasms | 38 | 2025 | 21162 | 1.350 |
Why?
|
Liver Cirrhosis | 12 | 2024 | 1960 | 1.240 |
Why?
|
Early Detection of Cancer | 11 | 2024 | 3236 | 1.140 |
Why?
|
Statistics, Nonparametric | 4 | 2019 | 2846 | 0.940 |
Why?
|
Receptor, erbB-2 | 16 | 2024 | 2597 | 0.810 |
Why?
|
Prothrombin | 5 | 2024 | 194 | 0.740 |
Why?
|
Models, Statistical | 4 | 2019 | 5091 | 0.710 |
Why?
|
Bayes Theorem | 5 | 2022 | 2354 | 0.640 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 22 | 2024 | 11872 | 0.620 |
Why?
|
Mass Screening | 4 | 2024 | 5454 | 0.560 |
Why?
|
Alanine Transaminase | 2 | 2024 | 608 | 0.560 |
Why?
|
Hepatitis C, Chronic | 4 | 2022 | 1033 | 0.550 |
Why?
|
Protein Precursors | 4 | 2024 | 1134 | 0.530 |
Why?
|
Paclitaxel | 10 | 2024 | 1727 | 0.490 |
Why?
|
Idiopathic Pulmonary Fibrosis | 6 | 2017 | 520 | 0.450 |
Why?
|
Survival Analysis | 2 | 2019 | 10100 | 0.450 |
Why?
|
Hepatitis B, Chronic | 3 | 2024 | 413 | 0.430 |
Why?
|
SEER Program | 6 | 2024 | 1443 | 0.400 |
Why?
|
Algorithms | 7 | 2022 | 14072 | 0.390 |
Why?
|
Neoadjuvant Therapy | 7 | 2024 | 2902 | 0.390 |
Why?
|
Sjogren's Syndrome | 2 | 2024 | 240 | 0.380 |
Why?
|
Sensitivity and Specificity | 8 | 2022 | 14652 | 0.380 |
Why?
|
Breast | 5 | 2023 | 1971 | 0.370 |
Why?
|
Neoplasm Staging | 11 | 2024 | 11218 | 0.370 |
Why?
|
Azithromycin | 3 | 2019 | 201 | 0.360 |
Why?
|
Regression Analysis | 2 | 2019 | 6329 | 0.350 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39309 | 0.350 |
Why?
|
Tissue and Organ Procurement | 2 | 2020 | 987 | 0.330 |
Why?
|
Lung Transplantation | 2 | 2017 | 1310 | 0.300 |
Why?
|
Pyrimidinones | 2 | 2021 | 385 | 0.300 |
Why?
|
Computer Simulation | 5 | 2019 | 6259 | 0.290 |
Why?
|
Humans | 90 | 2025 | 766766 | 0.290 |
Why?
|
Veterans | 2 | 2018 | 2667 | 0.280 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12064 | 0.270 |
Why?
|
Biostatistics | 2 | 2019 | 162 | 0.270 |
Why?
|
Female | 69 | 2025 | 396520 | 0.260 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2024 | 30 | 0.240 |
Why?
|
Ovarian Neoplasms | 4 | 2022 | 4904 | 0.240 |
Why?
|
Fumarate Hydratase | 1 | 2024 | 55 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2023 | 9404 | 0.220 |
Why?
|
Uterine Neoplasms | 2 | 2024 | 1424 | 0.220 |
Why?
|
Ketones | 2 | 2021 | 183 | 0.220 |
Why?
|
Furans | 2 | 2021 | 199 | 0.220 |
Why?
|
Middle Aged | 40 | 2024 | 223257 | 0.210 |
Why?
|
Early Diagnosis | 3 | 2022 | 1186 | 0.210 |
Why?
|
Saliva | 2 | 2024 | 852 | 0.200 |
Why?
|
Androstadienes | 1 | 2024 | 348 | 0.200 |
Why?
|
Breast Neoplasms, Male | 1 | 2024 | 213 | 0.200 |
Why?
|
Germ-Line Mutation | 4 | 2024 | 1885 | 0.200 |
Why?
|
Aged | 35 | 2024 | 171343 | 0.190 |
Why?
|
Pneumonectomy | 2 | 2019 | 1147 | 0.190 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 3246 | 0.190 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2025 | 10384 | 0.190 |
Why?
|
Maximum Tolerated Dose | 1 | 2024 | 895 | 0.190 |
Why?
|
Maytansine | 1 | 2021 | 88 | 0.180 |
Why?
|
BRCA2 Protein | 2 | 2022 | 802 | 0.180 |
Why?
|
Pyrazoles | 2 | 2021 | 2030 | 0.170 |
Why?
|
DNA Mismatch Repair | 3 | 2022 | 432 | 0.170 |
Why?
|
Longitudinal Studies | 5 | 2022 | 14762 | 0.170 |
Why?
|
Self-Help Groups | 1 | 2021 | 194 | 0.170 |
Why?
|
Research Subjects | 1 | 2021 | 248 | 0.160 |
Why?
|
Vital Capacity | 4 | 2017 | 995 | 0.160 |
Why?
|
Leiomyoma | 1 | 2024 | 644 | 0.160 |
Why?
|
Prognosis | 8 | 2024 | 29948 | 0.160 |
Why?
|
MutS Homolog 2 Protein | 2 | 2009 | 200 | 0.160 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1155 | 0.160 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2018 | 64 | 0.160 |
Why?
|
Quinolines | 1 | 2024 | 769 | 0.160 |
Why?
|
Ultrasonography | 2 | 2024 | 5992 | 0.150 |
Why?
|
Prospective Studies | 12 | 2024 | 54871 | 0.150 |
Why?
|
Treatment Outcome | 8 | 2024 | 65273 | 0.150 |
Why?
|
Endometrial Neoplasms | 2 | 2022 | 1380 | 0.150 |
Why?
|
Time | 1 | 2019 | 550 | 0.150 |
Why?
|
Adult | 26 | 2025 | 223307 | 0.140 |
Why?
|
Time Factors | 7 | 2024 | 40149 | 0.140 |
Why?
|
Deoxycytidine | 1 | 2021 | 886 | 0.140 |
Why?
|
Hepatitis B | 1 | 2022 | 709 | 0.140 |
Why?
|
Cohort Studies | 9 | 2024 | 41710 | 0.140 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2021 | 480 | 0.130 |
Why?
|
Piperazines | 2 | 2024 | 2547 | 0.130 |
Why?
|
Retrospective Studies | 18 | 2024 | 81635 | 0.130 |
Why?
|
Platelet Count | 1 | 2018 | 784 | 0.130 |
Why?
|
Attitude | 1 | 2020 | 768 | 0.130 |
Why?
|
Telemedicine | 2 | 2025 | 3111 | 0.120 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2009 | 388 | 0.120 |
Why?
|
NF-kappa B | 1 | 2023 | 2493 | 0.120 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2021 | 2426 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 949 | 0.120 |
Why?
|
Receptors, Estrogen | 4 | 2024 | 2251 | 0.120 |
Why?
|
Recurrence | 2 | 2019 | 8507 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1655 | 0.120 |
Why?
|
DNA Replication | 1 | 2021 | 1426 | 0.110 |
Why?
|
United States | 10 | 2024 | 72951 | 0.110 |
Why?
|
Staphylococcus | 1 | 2014 | 145 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 3552 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2948 | 0.110 |
Why?
|
Genetic Testing | 2 | 2024 | 3591 | 0.110 |
Why?
|
Streptococcus | 1 | 2014 | 197 | 0.110 |
Why?
|
Risk Assessment | 6 | 2024 | 24295 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8045 | 0.110 |
Why?
|
Anti-Bacterial Agents | 3 | 2019 | 7475 | 0.110 |
Why?
|
Forced Expiratory Volume | 2 | 2016 | 1828 | 0.100 |
Why?
|
Biological Products | 1 | 2022 | 948 | 0.100 |
Why?
|
Pulmonary Emphysema | 1 | 2018 | 683 | 0.100 |
Why?
|
Male | 24 | 2024 | 364142 | 0.100 |
Why?
|
Cell Cycle Proteins | 2 | 2021 | 3439 | 0.100 |
Why?
|
United States Department of Veterans Affairs | 1 | 2018 | 937 | 0.100 |
Why?
|
Reproducibility of Results | 3 | 2024 | 20144 | 0.100 |
Why?
|
Waiting Lists | 1 | 2017 | 779 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1445 | 0.100 |
Why?
|
Pyridines | 1 | 2024 | 2888 | 0.100 |
Why?
|
Monte Carlo Method | 1 | 2017 | 1250 | 0.090 |
Why?
|
Lung | 3 | 2017 | 10067 | 0.090 |
Why?
|
Social Support | 1 | 2021 | 2191 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2392 | 0.090 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2011 | 85 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 12534 | 0.090 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2019 | 2205 | 0.090 |
Why?
|
Lung Neoplasms | 3 | 2019 | 13485 | 0.080 |
Why?
|
Premature Birth | 1 | 2022 | 1830 | 0.080 |
Why?
|
Radiosurgery | 1 | 2019 | 1329 | 0.080 |
Why?
|
Phthalazines | 2 | 2022 | 397 | 0.080 |
Why?
|
DNA, Bacterial | 1 | 2014 | 1477 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6962 | 0.080 |
Why?
|
Taxoids | 2 | 2022 | 665 | 0.080 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2009 | 2902 | 0.080 |
Why?
|
Emphysema | 1 | 2010 | 234 | 0.080 |
Why?
|
Antigens, Neoplasm | 1 | 2016 | 1998 | 0.070 |
Why?
|
Hepatitis C | 1 | 2018 | 1595 | 0.070 |
Why?
|
Cyclophosphamide | 2 | 2023 | 2234 | 0.070 |
Why?
|
Respiratory Insufficiency | 1 | 2016 | 1241 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2662 | 0.070 |
Why?
|
Antigen Presentation | 2 | 2023 | 1250 | 0.070 |
Why?
|
Disease Progression | 5 | 2016 | 13640 | 0.070 |
Why?
|
Pulmonary Fibrosis | 1 | 2010 | 505 | 0.070 |
Why?
|
Lung Diseases | 1 | 2017 | 1941 | 0.070 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 15416 | 0.070 |
Why?
|
Cell Adhesion Molecules | 1 | 2012 | 1612 | 0.070 |
Why?
|
Aged, 80 and over | 9 | 2024 | 59550 | 0.070 |
Why?
|
Biopsy | 3 | 2024 | 6779 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9101 | 0.060 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 1012 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6850 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3275 | 0.060 |
Why?
|
Young Adult | 9 | 2025 | 59939 | 0.060 |
Why?
|
Mutation | 6 | 2024 | 30213 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3459 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5690 | 0.060 |
Why?
|
Autoantibodies | 2 | 2024 | 2115 | 0.060 |
Why?
|
Age Factors | 2 | 2018 | 18397 | 0.060 |
Why?
|
Patient Selection | 1 | 2017 | 4252 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2009 | 5795 | 0.060 |
Why?
|
Mastectomy | 2 | 2024 | 1861 | 0.060 |
Why?
|
Oxazepines | 1 | 2024 | 22 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5945 | 0.060 |
Why?
|
Leiomyomatosis | 1 | 2024 | 69 | 0.060 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2024 | 116 | 0.050 |
Why?
|
Survival Rate | 4 | 2021 | 12825 | 0.050 |
Why?
|
Oxazoles | 1 | 2024 | 198 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2881 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 22350 | 0.050 |
Why?
|
Uracil | 1 | 2024 | 210 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Mortality | 1 | 2014 | 2910 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.050 |
Why?
|
Genomics | 3 | 2024 | 5923 | 0.050 |
Why?
|
Salivary Glands | 1 | 2023 | 231 | 0.050 |
Why?
|
Sex Factors | 3 | 2024 | 10619 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.050 |
Why?
|
Carbon Monoxide | 2 | 2017 | 560 | 0.050 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4891 | 0.040 |
Why?
|
Premedication | 1 | 2021 | 245 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2024 | 992 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 562 | 0.040 |
Why?
|
Genetic Counseling | 1 | 2024 | 634 | 0.040 |
Why?
|
Respiratory Function Tests | 2 | 2016 | 1691 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20708 | 0.040 |
Why?
|
Isoxazoles | 1 | 2021 | 233 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2021 | 5306 | 0.040 |
Why?
|
Immunoassay | 1 | 2023 | 742 | 0.040 |
Why?
|
Liver | 1 | 2015 | 7571 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 789 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 633 | 0.040 |
Why?
|
Hormones | 1 | 2023 | 866 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13643 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 344 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 326 | 0.040 |
Why?
|
Pilot Projects | 2 | 2022 | 8728 | 0.040 |
Why?
|
Imidazoles | 1 | 2024 | 1168 | 0.040 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1150 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 735 | 0.040 |
Why?
|
Amenorrhea | 1 | 2021 | 470 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 428 | 0.040 |
Why?
|
Quinazolines | 1 | 2024 | 1367 | 0.040 |
Why?
|
Registries | 3 | 2021 | 8351 | 0.040 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 980 | 0.040 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2017 | 93 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 753 | 0.030 |
Why?
|
Methotrexate | 1 | 2023 | 1719 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9525 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2021 | 1159 | 0.030 |
Why?
|
ROC Curve | 1 | 2024 | 3620 | 0.030 |
Why?
|
Risk Factors | 3 | 2019 | 74881 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2024 | 926 | 0.030 |
Why?
|
Oncogenes | 1 | 2021 | 1231 | 0.030 |
Why?
|
Pyrazines | 1 | 2021 | 1204 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1105 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1528 | 0.030 |
Why?
|
Thiazoles | 1 | 2022 | 1529 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2214 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2056 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2060 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15908 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2885 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11094 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2021 | 22248 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2659 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1900 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2715 | 0.030 |
Why?
|
Attitude to Health | 1 | 2021 | 2021 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2009 | 9611 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2020 | 6214 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4559 | 0.020 |
Why?
|
Weight Gain | 1 | 2022 | 2356 | 0.020 |
Why?
|
Pancreatic Neoplasms | 1 | 2009 | 5444 | 0.020 |
Why?
|
Survivors | 1 | 2022 | 2379 | 0.020 |
Why?
|
Streptomycin | 1 | 2011 | 69 | 0.020 |
Why?
|
Kanamycin | 1 | 2011 | 63 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4626 | 0.020 |
Why?
|
Ofloxacin | 1 | 2011 | 66 | 0.020 |
Why?
|
Ethambutol | 1 | 2011 | 59 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 18075 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36567 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2334 | 0.020 |
Why?
|
Motivation | 1 | 2021 | 2020 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2024 | 11061 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1320 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2712 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6512 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3944 | 0.020 |
Why?
|
Isoniazid | 1 | 2011 | 279 | 0.020 |
Why?
|
Rifampin | 1 | 2011 | 350 | 0.020 |
Why?
|
Diffusion | 1 | 2010 | 808 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3957 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4443 | 0.020 |
Why?
|
Apoptosis | 1 | 2023 | 9513 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7841 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2023 | 17088 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15835 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7438 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5329 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4853 | 0.020 |
Why?
|
Anxiety | 1 | 2021 | 4670 | 0.020 |
Why?
|
South Africa | 1 | 2011 | 1875 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9244 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 1885 | 0.020 |
Why?
|
Research Design | 1 | 2021 | 6207 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2012 | 1730 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2012 | 1996 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 1805 | 0.010 |
Why?
|
Microbial Sensitivity Tests | 1 | 2011 | 1972 | 0.010 |
Why?
|
Collagen | 1 | 2012 | 2635 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6307 | 0.010 |
Why?
|
Fibrosis | 1 | 2010 | 2077 | 0.010 |
Why?
|
Quality of Life | 1 | 2025 | 13476 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5514 | 0.010 |
Why?
|
Monocytes | 1 | 2012 | 2600 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8066 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4780 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2011 | 1380 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 2010 | 0.010 |
Why?
|
Fibroblasts | 1 | 2012 | 4166 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26389 | 0.010 |
Why?
|
Pedigree | 1 | 2009 | 4539 | 0.010 |
Why?
|
Depression | 1 | 2021 | 8228 | 0.010 |
Why?
|
Wound Healing | 1 | 2012 | 2800 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2009 | 4114 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23619 | 0.010 |
Why?
|
Risk | 1 | 2009 | 9602 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10445 | 0.010 |
Why?
|
Adolescent | 1 | 2025 | 88904 | 0.010 |
Why?
|
Genotype | 1 | 2009 | 13036 | 0.010 |
Why?
|
Phenotype | 1 | 2009 | 16724 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 26310 | 0.010 |
Why?
|
Mice | 1 | 2012 | 81889 | 0.000 |
Why?
|
Animals | 1 | 2012 | 168930 | 0.000 |
Why?
|